Tenpoint Therapeutics and Visus Therapeutics announced the completion of their merger, according to a press release.
The merger will support the development of the presbyopia-correcting eye drop Brimochol PF (carbachol and brimonidine, Visus Therapeutics), which is on track for a new drug application filing with the FDA in the first half of 2025. The combined company’s pipeline also includes TPT-161, a novel small molecule designed to reverse cataract formation, and TPT-005, a cell therapy targeting retinal pigment epithelium cell replacement for geographic atrophy.
A crossover financing